Cas no 174743-89-6 (Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester)

Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester, is a specialized organic compound with potential applications in pharmaceutical and agrochemical synthesis. Its structure features a carbamate group linked to a 3-hydroxy-1-methylpropyl moiety and a benzyl ester, offering versatility as an intermediate in the development of bioactive molecules. The presence of both hydroxyl and ester functional groups enhances its reactivity, enabling selective modifications for targeted derivatives. This compound may serve as a precursor in the synthesis of prodrugs or enzyme inhibitors due to its hydrolyzable ester bond and potential for controlled release. Its stability under controlled conditions makes it suitable for research and industrial-scale applications.
Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester structure
174743-89-6 structure
Product Name:Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester
CAS No:174743-89-6
MF:C12H17NO3
MW:223.268283605576
CID:1360865
PubChem ID:10775453
Update Time:2025-10-31

Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester Chemical and Physical Properties

Names and Identifiers

    • Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester
    • benzyl N-(4-hydroxybutan-2-yl)carbamate
    • 174743-89-6
    • N-(benzyloxycarbonyl)-3-aminobutan-1-ol
    • BS-21742
    • (3-Hydroxy-1-methyl-propyl)-carbamic acid benzyl ester
    • Carbamic acid, N-(3-hydroxy-1-methylpropyl)-, phenylmethyl ester
    • EN300-7347468
    • SCHEMBL938009
    • DTXSID50444753
    • (3-Hydroxy-1-methylpropyl)carbamic acid benzyl ester
    • Inchi: 1S/C12H17NO3/c1-10(7-8-14)13-12(15)16-9-11-5-3-2-4-6-11/h2-6,10,14H,7-9H2,1H3,(H,13,15)
    • InChI Key: ZLDCAJWAPVPCFY-UHFFFAOYSA-N
    • SMILES: O(CC1C=CC=CC=1)C(NC(C)CCO)=O

Computed Properties

  • Exact Mass: 223.12091
  • Monoisotopic Mass: 223.12084340g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 4
  • Heavy Atom Count: 16
  • Rotatable Bond Count: 7
  • Complexity: 202
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 1.5
  • Topological Polar Surface Area: 58.6?2

Experimental Properties

  • PSA: 58.56

Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
A2B Chem LLC
AA92992-1g
Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester
174743-89-6 98%
1g
$226.00 2024-04-20
A2B Chem LLC
AA92992-5g
Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester
174743-89-6 98%
5g
$766.00 2024-04-20
Enamine
EN300-7347468-0.05g
benzyl N-(4-hydroxybutan-2-yl)carbamate
174743-89-6
0.05g
$323.0 2023-05-24
Enamine
EN300-7347468-0.1g
benzyl N-(4-hydroxybutan-2-yl)carbamate
174743-89-6
0.1g
$339.0 2023-05-24
Enamine
EN300-7347468-0.25g
benzyl N-(4-hydroxybutan-2-yl)carbamate
174743-89-6
0.25g
$354.0 2023-05-24
Enamine
EN300-7347468-0.5g
benzyl N-(4-hydroxybutan-2-yl)carbamate
174743-89-6
0.5g
$370.0 2023-05-24
Enamine
EN300-7347468-1.0g
benzyl N-(4-hydroxybutan-2-yl)carbamate
174743-89-6
1g
$385.0 2023-05-24
Enamine
EN300-7347468-2.5g
benzyl N-(4-hydroxybutan-2-yl)carbamate
174743-89-6
2.5g
$754.0 2023-05-24
Enamine
EN300-7347468-5.0g
benzyl N-(4-hydroxybutan-2-yl)carbamate
174743-89-6
5g
$1115.0 2023-05-24
Enamine
EN300-7347468-10.0g
benzyl N-(4-hydroxybutan-2-yl)carbamate
174743-89-6
10g
$1654.0 2023-05-24

Additional information on Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester

Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester and CAS No. 174743-89-6: A Comprehensive Overview

Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester, identified by the Chemical Abstracts Service registry number CAS No. 174743-89-6, is a compound of significant interest in the field of pharmaceutical chemistry and bioorganic synthesis. This compound, characterized by its unique structural features, has garnered attention for its potential applications in drug development and synthetic methodologies. The detailed exploration of its chemical properties, synthetic pathways, and emerging applications in medicinal chemistry provides a comprehensive understanding of its relevance in contemporary research.

The molecular structure of Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester consists of a phenylmethyl ester group linked to a carbamic acid moiety substituted with a (3-hydroxy-1-methylpropyl) group. This configuration imparts distinct physicochemical properties that make it a versatile intermediate in organic synthesis. The presence of both hydroxyl and ester functionalities allows for diverse chemical transformations, making it a valuable building block in the construction of more complex molecular architectures.

In recent years, the interest in this compound has been fueled by its potential role in the development of novel therapeutic agents. The (3-hydroxy-1-methylpropyl) side chain introduces steric and electronic effects that can influence the binding affinity and selectivity of drug candidates. This has led to its investigation as a component in the design of small-molecule inhibitors targeting various biological pathways. For instance, studies have explored its utility in the synthesis of protease inhibitors, where the hydroxyl group can participate in hydrogen bonding interactions with target proteins, enhancing binding efficacy.

The synthesis of Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester involves multi-step organic reactions that highlight the compound's synthetic utility. One common approach involves the reaction of phenylmethyl bromide with a hydroxymethyl propyl carbamate precursor under controlled conditions. This method leverages nucleophilic substitution reactions to form the desired ester linkage. The reaction conditions are carefully optimized to ensure high yield and purity, which are critical for pharmaceutical applications.

Advances in synthetic methodologies have further enhanced the accessibility of this compound. Modern techniques such as flow chemistry and catalytic processes have been employed to streamline the synthesis, reducing reaction times and improving scalability. These innovations are particularly relevant in industrial settings where cost-effectiveness and reproducibility are paramount.

The pharmacological potential of Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester has been explored through various preclinical studies. Its structural features suggest interactions with enzymes and receptors involved in metabolic disorders and inflammatory diseases. For example, preliminary research indicates that derivatives of this compound may exhibit inhibitory activity against certain kinases, which are implicated in cancer progression. The hydroxyl group's ability to form hydrogen bonds with biological targets enhances its binding potential, making it a promising scaffold for drug discovery.

In addition to its therapeutic applications, this compound has found utility in materials science and agrochemical research. Its ability to undergo cross-coupling reactions makes it a valuable precursor for synthesizing more complex molecules with tailored properties. These applications underscore the broad versatility of Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester beyond traditional pharmaceuticals.

The regulatory landscape for compounds like Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester is governed by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory bodies ensure that compounds used in drug development meet stringent safety and efficacy standards before they can be commercialized. Compliance with these regulations is essential for researchers and manufacturers involved in the synthesis and application of such compounds.

The future directions for research on Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester include further exploration of its pharmacological properties and optimization of synthetic routes for industrial-scale production. Collaborative efforts between academic institutions and pharmaceutical companies are likely to drive innovation in this area. The integration of computational chemistry techniques will also play a crucial role in predicting and designing new derivatives with enhanced biological activity.

In conclusion, Carbamic acid, (3-hydroxy-1-methylpropyl)-, phenylmethyl ester, identified by CAS No. 174743-89-6, represents a significant advancement in pharmaceutical chemistry. Its unique structural features and versatile synthetic pathways make it a valuable intermediate for drug development and other chemical applications. As research continues to uncover new possibilities for this compound, its importance in medicinal chemistry is set to grow further.

Recommended suppliers
Changzhou Guanjia Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Changzhou Guanjia Chemical Co., Ltd
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
Handan Zechi Trading Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
SunaTech Inc.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
SunaTech Inc.
PRIBOLAB PTE.LTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
PRIBOLAB PTE.LTD